Neurophet, a deep learning-based brain imaging analysis technology corporation, is showing strength in the early session on the 25th, the first day of its listing on the KOSDAQ market.
As of 9:15 a.m. on this day, Neurophet is trading at 24,250 won, up 10,250 won (73.21%) from the offering price of 14,000 won.
Neurophet recorded a competition rate of 1,087.6 to 1 in the demand forecast conducted for institutional investors from the 4th to the 10th of this month. A total of 2,444 domestic and foreign institutions participated, and the offering price was confirmed at the upper end of the desired range (14,000 won to 11,400 won) at 14,000 won.
In the public offering subscription for general investors conducted over two days on the 15th and 16th, a competition rate of 1,922.75 to 1 was observed. About 6.7296 trillion won was collected as subscription deposits.
Founded in 2016, Neurophet engages in the development of software tools that analyze diagnostic data such as magnetic resonance imaging (MRI) and positron emission tomography (PET) using artificial intelligence (AI). It provides solutions related to differential diagnosis of dementia, confirmation of Alzheimer's disease, and observation of side effects and prognosis.
Bin Jun-gil, co-CEO of Neurophet, noted, "Recently, with the start of prescribing Alzheimer's disease treatment drugs in Korea, the brain disease treatment market is expanding," and added, "We will enhance our key solutions and technologies through the funds raised in the public offering and focus on expanding our business overseas."